TY - JOUR T1 - Time to sputum culture conversion as a prognostic marker for end-of-treatment outcome in the first cohorts of MDR-TB patients managed in a Nigerian tertiary hospital JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA2685 VL - 48 IS - suppl 60 SP - PA2685 AU - Olusoji Ige AU - Regina Oladokun Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA2685.abstract N2 - Objective: The aim of this study was to assess the validity of sputum culture conversion at varying timepoints as prognostic markers for end-of-treatment outcome in patients with MDR TB.Methods: A retrospective study was conducted for the period 2010-2013, at the MDR-TB treatment center of the University College Hospital Ibadan, Nigeria.GeneXpert was done for confirmation of rifampicin resistance and MDR-TB was confirmed by sputum culture and DST.Sputum culture was done at baseline and monthly during the intensive phase and also every 2 months at follow up visits.Results: The Cohorts of 115 patients that had completed the therapy for multidrug-resistant TB were studied. 39(33.9%) were males and 76(66.1%) females. Their ages ranged between 15 and 65 years. The mean age was 32.44 ± 12.63 years.The median time of conversion in months was 1.91 ± 1.20.91(97.5%) and 112(97.4%) were sputum culture converted at the end 2nd and 5th month respectively.Overall 69.0% (79/115) of patients had treatment success as shown by the cure rate of 41% (47/115) and treatment completed rate of 28% (32/115). Treatment failure occurred in only 1 patient. The default rate was 6% (7/115) and a total of 28 (24%) deaths were recorded. Patients who converted sputum culture at 2 months had a higher chance of treatment success than those with no conversion at 2 months.Conclusion: The study has shown that most patients with MDR-TB achieved sputum culture conversion within 2 months of starting treatment. Treatment outcome relates more to sputum conversion at the 2nd and 5th months. There was no significant interaction with HIV status. ER -